1. Home
  2. ENTX vs KOPN Comparison

ENTX vs KOPN Comparison

Compare ENTX & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • KOPN
  • Stock Information
  • Founded
  • ENTX 2010
  • KOPN 1984
  • Country
  • ENTX Israel
  • KOPN United States
  • Employees
  • ENTX N/A
  • KOPN 144
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • KOPN Semiconductors
  • Sector
  • ENTX Health Care
  • KOPN Technology
  • Exchange
  • ENTX Nasdaq
  • KOPN Nasdaq
  • Market Cap
  • ENTX 90.2M
  • KOPN 282.1M
  • IPO Year
  • ENTX 2018
  • KOPN 1992
  • Fundamental
  • Price
  • ENTX $2.28
  • KOPN $1.74
  • Analyst Decision
  • ENTX Strong Buy
  • KOPN Strong Buy
  • Analyst Count
  • ENTX 1
  • KOPN 4
  • Target Price
  • ENTX $10.00
  • KOPN $2.63
  • AVG Volume (30 Days)
  • ENTX 88.5K
  • KOPN 10.3M
  • Earning Date
  • ENTX 03-07-2025
  • KOPN 03-13-2025
  • Dividend Yield
  • ENTX N/A
  • KOPN N/A
  • EPS Growth
  • ENTX N/A
  • KOPN N/A
  • EPS
  • ENTX N/A
  • KOPN N/A
  • Revenue
  • ENTX $99,000.00
  • KOPN $44,266,305.00
  • Revenue This Year
  • ENTX N/A
  • KOPN $21.20
  • Revenue Next Year
  • ENTX N/A
  • KOPN $13.55
  • P/E Ratio
  • ENTX N/A
  • KOPN N/A
  • Revenue Growth
  • ENTX 607.14
  • KOPN 0.60
  • 52 Week Low
  • ENTX $0.82
  • KOPN $0.56
  • 52 Week High
  • ENTX $3.35
  • KOPN $2.82
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 50.71
  • KOPN 57.33
  • Support Level
  • ENTX $2.32
  • KOPN $1.52
  • Resistance Level
  • ENTX $2.62
  • KOPN $1.94
  • Average True Range (ATR)
  • ENTX 0.20
  • KOPN 0.19
  • MACD
  • ENTX -0.01
  • KOPN -0.01
  • Stochastic Oscillator
  • ENTX 56.13
  • KOPN 41.54

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: